Shamrock Industrial Company Limited is an India-based pharmaceuticals company. The Company offers a diverse range of manufacturing of pharmaceuticals and drugs products and allied business activities. It offers its products for various therapeutic uses, including anti-coagulants (anti-platelet), radio-protective agents, platelet regulator, anti-depressants, anti-neo plastics and immunosuppressants, antihistamines, sympathomimetics, anti-hypertensives, diuretic, anti-diabetic, calcium regulating agents, local anesthetics and anti-bacterial. Its active pharmaceutical ingredient (API) product list (manufactured) includes acenocomarol, amifostine, ciclopirox, cilazapril, losartan potassium, metaxalone, metoprolol succinate and pregabalin. The Company's API product list (contract manufactured) includes abacavir, acarbose, oxaliplatin, oxaprozin, finasteride, frusemide and colchicine.
SHAMROCK INDUSTRIAL CO.LTD. Financial Highlights
- Revenue: SHAMROCK INDUSTRIAL CO.LTD. reported revenue of ₹0.03 crore in FY26 vs ₹0.00 crore in FY25.
- Operating Profit: SHAMROCK INDUSTRIAL CO.LTD. reported an operating loss of ₹1.09 crore in FY26 vs ₹0.13 crore in FY25. It showed a decrease of 738.46% on a year-on-year basis.
- Net Profit: SHAMROCK INDUSTRIAL CO.LTD. reported a net loss of ₹1.09 crore in FY26 vs ₹0.13 crore in FY25. It showed a decrease of 738.46% on a yearly basis.
SHAMROCK INDUSTRIAL CO.LTD. Quarterly Result Highlights
- SHAMROCK INDUSTRIAL CO.LTD. reported revenue of ₹0.03 crore in Mar 2026, compared with ₹0.00 crore in Dec 2025.
- SHAMROCK INDUSTRIAL CO.LTD. reported an operating loss of ₹0.10 crore in Mar 2026, compared with ₹0.55 crore in Dec 2025, representing an increase of 81.82% on a quarter-on-quarter (QoQ) basis.
- SHAMROCK INDUSTRIAL CO.LTD. reported a loss of ₹0.10 crore in Mar 2026, compared with ₹0.55 crore in Dec 2025, reflecting an increase of 81.82% on a QoQ basis.
- The earnings per share (EPS) of SHAMROCK INDUSTRIAL CO.LTD. stood at ₹0.23 during Mar 2026.